Envarsus
Payments companies reported to CMS as associated with Envarsus. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Envarsus, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Envarsus
These are the largest totals companies reported as associated with Envarsus. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Christina Klein | Atlanta, GA | Nephrology (Internal Medicine) | $24,736.68 |
| Alexander Wiseman | Denver, CO | Transplant Surgery | $20,671.99 |
| Jay Graham | Newark, NJ | Surgery | $13,861.46 |
| Michael Goldstein | Hackensack, NJ | Transplant Surgery | $8,204.84 |
| Anthony Langone | Nashville, TN | Nephrology (Internal Medicine) | $6,900.00 |
| Joseph Melancon | Washington, DC | Transplant Surgery | $6,819.22 |
| Matthew Cooper | Milwaukee, WI | Transplant Surgery | $6,813.74 |
| Amit Govil | Cincinnati, OH | Nephrology (Internal Medicine) | $6,725.45 |
| Sridhar Allam | Mcallen, TX | Transplant Surgery | $6,345.84 |
| Grant Sarkisyan | Los Alamitos, CA | Surgery | $6,300.00 |
Prescribed Envarsus?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.